Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIXGet Rating) have received a consensus rating of “Hold” from the twenty-one analysts that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and nine have assigned a buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $111.63.

Several brokerages recently weighed in on NBIX. Jefferies Financial Group lowered Neurocrine Biosciences to a “hold” rating and set a $94.00 target price on the stock. in a research report on Thursday, March 3rd. The Goldman Sachs Group upgraded Neurocrine Biosciences from a “neutral” rating to a “buy” rating and set a $115.00 price target for the company in a report on Thursday, February 24th. Mizuho lowered their price target on Neurocrine Biosciences from $103.00 to $95.00 in a report on Monday, February 14th. Raymond James reiterated a “buy” rating and issued a $125.00 price target on shares of Neurocrine Biosciences in a report on Friday, February 11th. Finally, Morgan Stanley increased their price target on Neurocrine Biosciences from $95.00 to $100.00 and gave the company an “equal weight” rating in a report on Monday, February 14th.

In other news, Director Stephen A. Sherwin sold 15,000 shares of the stock in a transaction dated Monday, January 24th. The shares were sold at an average price of $74.43, for a total transaction of $1,116,450.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Kevin Charles Gorman sold 8,710 shares of the stock in a transaction dated Monday, February 7th. The stock was sold at an average price of $80.82, for a total transaction of $703,942.20. The disclosure for this sale can be found here. Insiders have sold 46,743 shares of company stock worth $3,957,821 in the last ninety days. Corporate insiders own 4.30% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lifted its holdings in Neurocrine Biosciences by 0.8% in the third quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 17,487 shares of the company’s stock worth $1,677,000 after acquiring an additional 136 shares during the last quarter. Whittier Trust Co. lifted its holdings in Neurocrine Biosciences by 102.8% in the fourth quarter. Whittier Trust Co. now owns 290 shares of the company’s stock worth $25,000 after acquiring an additional 147 shares during the last quarter. Cubist Systematic Strategies LLC lifted its holdings in Neurocrine Biosciences by 0.7% in the third quarter. Cubist Systematic Strategies LLC now owns 22,275 shares of the company’s stock worth $2,136,000 after acquiring an additional 159 shares during the last quarter. Asset Management One Co. Ltd. lifted its holdings in Neurocrine Biosciences by 0.4% in the third quarter. Asset Management One Co. Ltd. now owns 39,215 shares of the company’s stock worth $3,761,000 after acquiring an additional 166 shares during the last quarter. Finally, Daiwa Securities Group Inc. lifted its holdings in Neurocrine Biosciences by 1.6% in the third quarter. Daiwa Securities Group Inc. now owns 10,817 shares of the company’s stock worth $1,038,000 after acquiring an additional 174 shares during the last quarter. 95.93% of the stock is currently owned by hedge funds and other institutional investors.

NBIX opened at $98.12 on Thursday. Neurocrine Biosciences has a fifty-two week low of $71.88 and a fifty-two week high of $108.01. The company has a debt-to-equity ratio of 0.24, a quick ratio of 3.83 and a current ratio of 3.96. The company has a fifty day moving average of $92.28 and a two-hundred day moving average of $89.20. The stock has a market capitalization of $9.37 billion, a price-to-earnings ratio of 107.82, a PEG ratio of 4.74 and a beta of 0.71.

Neurocrine Biosciences (NASDAQ:NBIXGet Rating) last posted its earnings results on Friday, February 11th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.69). Neurocrine Biosciences had a net margin of 7.90% and a return on equity of 6.89%. The company had revenue of $312.00 million during the quarter, compared to analysts’ expectations of $317.72 million. During the same period in the previous year, the company posted $3.58 EPS. Neurocrine Biosciences’s quarterly revenue was up 25.9% compared to the same quarter last year. On average, equities research analysts forecast that Neurocrine Biosciences will post 1.81 earnings per share for the current year.

About Neurocrine Biosciences (Get Rating)

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas.

Read More

Analyst Recommendations for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.